COVAXIN shows interim efficacy of 81 per cent in phase 3 clinical results, says Bharat Biotech.
India’s indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.
